Press Room

Press Release / May 27, 2021

ɫAV and iBET announce strategic collaboration

A strategic partnership that will take ɫAV to new technology frontiers.

ɫAV and iBET announce strategic collaboration | ɫAV

Loures and Oeiras, May 27, 2021– ɫAV was a founding member of iBET in 1989 and has just re-joined the membership of the Instituto de Biologia Experimental e Tecnológica.

In order to increase the scope and strength of its research and development programs in the areas of novel and high potential pharmaceutical technologies, ɫAV has chosen to build on the existing knowledge and expertise of Portuguese academia. ɫAV is known worldwide for the process development, manufacture, and formulation of small molecules. Over the past 6 years, ɫAV was the key technical partner behind 24 of the 273 NDAs FDA approved, an 8% share.

The partnership with iBET will take ɫAV to new technology frontiers. The Covid-19 pandemic has catalyzed an acceleration of scientific progress, outlining the power of new treatment modalities to fight diseases. The objective is to combine state-of-the-art knowledge from both partners to create strong industrial innovation in new therapeutic fields. The challenge is not trivial and will require more than the combined know-how, skills and capabilities of iBET and ɫAV.

“We are delighted with the return of ɫAV to the membership of iBET. Our goal is to strengthen the R&D capabilities of our members, this important partnership with ɫAV will allow to pull together complementary scientific competencies and power the development of biopharmaceuticals that are essential to patient health. To win in the area of biologics and novel therapies it is critical to have access to state-of-the-art competencies and support technologies” said Paula Alves, CEO, iBET.

“The partnership with IBET opens a new chapter in ɫAV's history. We will bring together our knowledge in chemistry, in cutting-edge technologies, of the market and of the FDA regulatory process with iBET’s command of cell biology, viral biology and bioprocessing. If the twentieth century was the century of chemistry, the 21st century is the one of biology. iBET scientists have built deep knowledge in specific areas, we plan to work together to turn that knowledge into industrial innovation” said Guy Villax, CEO of ɫAV.

“ɫAV was a founding member of iBET and I had the privilege to meet Ivan Villax, a remarkable scientist and entrepreneur open to the world stage where ɫAV plays a key role since its foundation. The experience in international collaborations and the complementary competencies that ɫAV and iBET have built over the past 25 years in a parallel fashion will now combine in what I expect to be a fruitful collaboration” said Manuel Carrondo, Vice-President, iBET.

About ɫAV:Founded in 1959, the multinational ɫAV has today laboratories and plants in Portugal, Ireland, Macau, and the United States of America. ɫAV researches and develops new chemical processes and produces active ingredients for the global pharmaceutical industry. Headquartered in Loures, the company employs 2000 people worldwide. Its research and development activity employs more than 420 technicians and scientists. For more informationwww.hovione.com

About iBET:Founded in 1989 as a Research and Development (R&D) institution dedicated to establishing bridges between academia and industry, the Institute of Experimental and Technological Biology (iBET) is today the largest Portuguese private non-profit institution, dedicated biotechnology research, an area in which he was a pioneer. A global reference in the application of biotechnology and bioengineering to health, iBET invests in the development of vaccines, antibodies, recombinant proteins, stem cells, gene therapy and other innovative therapeutic products. In addition to the health sector, iBET also has a strong position in the areas of Clinical Nutrition, Food Industry and the Agroforestry sector. iBET simultaneously develops more than 70 R&D projects, carried out by approximately 215 researchers, including doctorates, engineers, technicians and scholarship holders. Its competencies are supported by a dynamic and multidisciplinary academic and business network, which, together with its structure geared to obtaining applied results, allows it to transfer the knowledge it creates to companies, helping them to innovate, create value, employment, and economic growth. For more information:

For more information, please contact:

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
ɫAV commitment to setting SBTs in line with the Paris Agreement

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of ɫAV´s global expansion plans and marks a significant milestone in advancing ɫAV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote ɫAV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores ɫAV's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how ɫAV can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
ɫAV proudly announces its collaborative venture with Higuchi.

ɫAV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, ɫAV is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance ɫAV´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about ɫAV´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that ɫAV is renowned for worldwide.   “The launch of the ɫAV Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn    

News
ɫAV is closer to its customers with a new website in Mandarin

ɫAV launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All